[Treatment costs of otogenic vertigo].

Author: Heinen-KammererTatjana, HoltmannspötterChristine, Motzkat-GnissKerstin, RychlikReinhard, StratmannLioba

Paper Details 
Original Abstract of the Article :
PURPOSE: In this decision-tree analysis, the costs of otogenic vertigo treatment were investigated from the third-party payer's perspective. Either the combination preparation, with cinnarizine 20 mg and dimenhydrinate 40 mg as active substances, or betahistine (12 mg betahistinedimesilate) was admi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00063-006-1120-y

データ提供:米国国立医学図書館(NLM)

Treatment costs of otogenic vertigo

This research explores the cost-effectiveness of two treatment options for otogenic vertigo: a combination preparation containing cinnarizine and dimenhydrinate, and betahistine. The study utilizes a decision-tree analysis to compare the costs and effectiveness of these treatments from the perspective of a third-party payer.

Combination Preparation More Cost-Effective

The study's findings demonstrate that the combination preparation is more cost-effective than betahistine for treating otogenic vertigo. This conclusion is based on the effectiveness-adjusted costs, which take into account both the cost of treatment and the effectiveness in achieving symptom resolution. The combination preparation showed significantly lower effectiveness-adjusted costs compared to betahistine.

Balancing Cost-Effectiveness and Patient Preferences

This research highlights the importance of considering both cost-effectiveness and patient preferences when making treatment decisions. While the combination preparation may be more cost-effective, patients may prefer betahistine due to its superior effectiveness and side effect profile. The study emphasizes the need for a collaborative approach between healthcare providers and patients to ensure that treatment decisions are both cost-effective and meet individual patient needs.

Dr.Camel's Conclusion

This research provides valuable insights into the cost-effectiveness of different treatment options for otogenic vertigo. The study's findings suggest that the combination preparation is more cost-effective than betahistine. However, the researchers acknowledge that patient preferences may influence treatment decisions. This underscores the importance of a collaborative approach between healthcare providers and patients in navigating the complex desert of treatment options and making informed choices that align with both cost and individual needs.

Date :
  1. Date Completed 2007-04-03
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

17235475

DOI: Digital Object Identifier

10.1007/s00063-006-1120-y

Related Literature

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.